ClinicalTrials.gg
Not yet recruitingNCT07013656Updated Jun 24, 2025

Effects of Combined Administration of Calcium and L-tryptophan on Gut Functions and Blood Glucose in Healthy Humans

An interventional study of L-tryptophan and Combination of L-tryptophan + Ca-500 in Healthy, sponsored by University of Adelaide. Not yet recruiting at 1 site in Australia. Open to male participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by University of Adelaide · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Male
01

Study summary

The intervention in this study consists of 75-minute intraduodenal infusions of isosmotic solutions containing either saline (control), L-tryptophan, or calcium combined with L-tryptophan. Participants enrolled into the study will receive, in a randomised, double-blind fashion either (i) saline (control), (ii) L-tryptophan at a rate of 0.1 kcal/minute, (iii) combination of L-tryptophan (0.1 kcal/minute) + 500 mg calcium, or (iv) combination of L-tryptophan (0.1 kcal/minute) + 1000 mg calcium in four separate sessions, each of which will be separated by at least 4 (and up to 10) days. Each study session will be 4-6 hours. Studies will be carried out in the Clinical Research Facility of the Adelaide Medical School, the University of Adelaide, by staff and students trained in the required techniques.

Read the detailed description

Each participant will be required to consume a standardised dinner meal (beef lasagne; total energy content: 602 kcal; McCain Food, Wendouree, Victoria, Australia) on the night before each visit by 7 pm. After fasting overnight for \~ 13.5 hours and refraining from exercise and alcohol during the previous 24 hours, the participant will arrive in the laboratory at 8.30 am. After confirming adherence to the study requirements, vital signs ( blood pressure, heart rate and body temperature) will be measured to establish baseline values for safety, and they will be monitored throughout the study. Then, a manometric catheter will be inserted through an anaesthetised nostril and allowed to pass through the stomach and into the duodenum by peristalsis. The infusion port will be positioned \~ 14 cm distal to the pylorus. The correct positioning of the catheter will be monitored continuously by measurement of the transmucosal potential difference in the stomach (\~ -40 mV) and the duodenum (\~ 0 mV). Once the catheter has been positioned correctly, an intravenous cannula will be placed into a forearm vein for regular blood sampling. At time = -30 minute, a baseline blood sample (6 ml), visual analogue scale (VAS) questionnaire to assess gastrointestinal (GI) symptoms, and breath sample to assess gastric emptying will be collected. Then the infusion of one of the study treatments, i.e. (i) saline, (ii) L-tryptophan, (iii) L-tryptophan + 500 mg calcium, or (iv) L-tryptophan + 1000 mg calcium, will commence and continue for 75 minutes (times = -30 to 45 minutes). At time = -1 minute, participants will consume, within 1 minute, a mixed-nutrient drink (350 mL, containing 500 kcal, 74 g carbohydrates) labelled with 100 mg 13C-acetate for measurement of gastric emptying by non-invasive breath sampling at regular intervals, for subsequent analysis of 13CO2 levels. Blood samples for the measurement of plasma glucose and hormone concentrations, and VAS questionnaires, will be collected before and after the mixed-nutrient drink. At time = 240 minute, after collecting final blood and breath samples and VAS questionnaire, the intravenous cannula will be removed and the participant will be served a light lunch, after which they will be allowed to leave the laboratory. A total of 84 mL of blood (14 sampling time points, 6 mL each) will be taken on each study day (study total of 344 mL, including screening).

02

Conditions studied

  • Healthy

Keywords

  • Intraduodenal
  • Calcium
  • L-tryptophan
  • Gastric emptying
  • Glucoregulatory hormones
  • Plasma glucose
  • Human
03

In context

Lead sponsor

University of Adelaide is the lead sponsor of 42 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, lean males (only men will be included in the study to avoid the confounding effects of the menstrual cycle on gastric emptying).
  • : 19-25 kg/m2,
  • Weight-stable (i.e. \<5% fluctuation) at study entry, which will be ascertained by a stable body weight in the preceding 3 months.

Exclusion criteria

Exclusion Criteria:

  • Significant GI symptoms, or history of GI disease or surgery
  • Current gallbladder or pancreatic disease
  • Cardiovascular or respiratory diseases
  • Any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above)
  • Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, GI function, body weight or appetite (e.g. domperidone, cisapride, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.)
  • Lactose intolerance/other food allergy(ies)
  • Individuals with low ferritin levels (\<30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study
  • High performance athletes
  • Current intake of > 2 standard drinks on > 5 days per week (>140g/week)
  • Current smokers of tobacco (cigarettes, cigars, pipes, sheesha, chewing, vaping etc.)
  • Current use of recreational drugs, e.g. marijuana
  • Current intake of any illicit substance
  • Vegetarians
  • Inability to tolerate nasoduodenal tube
  • Inability to comprehend study protocol
  • Restrained eaters (score >12 on the 3-factor eating questionnaire)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (estimated)

Study arms

  • Active comparator
    L-tryptophan

    In this arm, participants will receive a 75-minute intraduodenal infusion of an isotonic solution containing 1.83 g L-tryptophan, dissolved in 225 mL distilled water. Additionally, 2.2 g of sodium chloride (NaCl) will be added to ensure the solution is isosmotic (\~373 mOsm).

    Other: L-tryptophan

  • Active comparator
    L-tryptophan + Ca-500

    In this arm, participants will receive a 75-minute intraduodenal infusion of an isotonic solution containing 1.83 g L-tryptophan and 1.84 g of calcium chloride dihydrate (CaCl₂·2H₂O), dissolved in 225 mL of distilled water. Additionally, 1.1 g of NaCl will be added to ensure the solution is isosmotic (\~373 mOsm).

    Other: Combination of L-tryptophan + Ca-500

  • Active comparator
    L-tryptophan + Ca-1000

    In this arm, participants will receive a 75-minute intraduodenal infusion of an isotonic solution containing 1.83 g L-tryptophan and 3.68 g of calcium chloride dihydrate (CaCl₂·2H₂O), dissolved in 225 mL of distilled water. This solution has an osmolality of \~373 mOsm.

    Other: Combination of L-tryptophan + Ca-1000

  • Placebo comparator
    Control

    In this arm, participants will receive a 75-minute intraduodenal infusion of saline (an isotonic solution containing 2.5 g of NaCl, dissolved in 225 mL of distilled water). This solution has an osmolality of \~373 mOsm.

    Other: Control

Interventions

  • OtherL-tryptophan

    L-tryptophan, an aromatic amino acid and one of the building blocks of protein, is a part of our daily diet. The load of L-tryptophan (0.1 kcal/minute) is based on our previous study, in which L-tryptophan represented a submaximal load.

  • OtherCombination of L-tryptophan + Ca-500

    Calcium, an essential mineral and a key component of dairy products, is a regular part of our daily diet. In this condition, both L-tryptophan and calcium will be administered as 'active'. Recent studies have shown that calcium in a dose of 500 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'lower dose'.

  • OtherCombination of L-tryptophan + Ca-1000

    In this condition, both L-tryptophan and calcium will be administered. In our study calcium in a dose of 1000 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'higher dose'.

  • OtherControl

    An isotonic solution containing 2.5 g of NaCl, dissolved in 225 mL of distilled water.

06

What researchers measure

Primary outcomes

  1. Plasma glucose concentrations

    Plasma glucose concentrations (mmol/L) will be assessed using the glucose oxidase method.

    Time frame: Blood samples will be collected over 4.5 hours: at baseline (time = -30 minutes), then at regular intervals before and after drink administration (times = -25, -15, 0, 10, 20, 30, 45, 60, 75, 90, 120, 180, and 240 minutes).

Secondary outcomes

  1. Gastric emptying

    13C-acetate breath test, measuring 13CO2 levels in end-expiratory breath samples.

    Time frame: Breath samples will be collected in sealed tubes over 4.5 hours: at baseline (time = -30 minutes), prior to treatment administration, every 5 minutes after the drink (times = 0 to 60 minutes), and then every 10 minutes until 240 minutes post-drink.

  2. Plasma concentrations of glucoregulatory hormones e.g. glucagon-like peptide (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), C-peptide, glucagon, insulin and cholecystokinin (CCK)

    Plasma concentrations of hormones e.g. GLP-1, GIP and CCK (pmol/L) will be determined using radioimmunoassays, and plasma C-peptide, glucagon and insulin concentrations (pmol/L) will be measured using ELISA immunoassays.

    Time frame: Blood samples will be collected over 4.5 hours: at baseline (time = -30 minute), then at regular intervals before and after the drink (times = -25, -15, 0, 10, 20, 30, 45, 60, 75, 90, 120, 180, and 240 minutes).

  3. GI symptoms (nausea and bloating) will be assessed as a composite secondary outcome.

    These will be measured using 100mm VAS questionnaires.

    Time frame: VAS questionnaires will be collected over 4.5 hours: at baseline (time = -30 minutes), at regular intervals before and after the drink (times = -15, 0, 10, 20, 30, 45, 60, 75, and 90 minutes), then every 10 minutes until 240 minutes post-drink.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The de-identified individual participant data (IPD) collected during the study will not be shared with other researchers. This is due to the ethical approval and informed consent process, which require that data remain confidential and not be shared outside the primary research group, even in de-identified form.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Jun 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartEst.
Jun 28, 2025
Primary completionEst.
Jun 28, 2026
CompletionEst.
Nov 25, 2026
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07013656
Lead sponsor
University of Adelaide
Responsible party
Christine Feinle-Bisset (Professor Christine Feinle-Bisset (Professorial Senior Research Fellow), University of Adelaide) — Principal investigator
First posted
Jun 10, 2025
Start date
Jun 28, 2025 (estimated)
Primary completion
Jun 28, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Jun 24, 2025

Study contacts

Prof Christine Feinle-Bisset
Contact
christine.feinle@adelaide.edu.au
+61 8 8313 6053
Penelope Fitzgerald, MsC
Contact
penelope.fitzgerald@adelaide.edu.au
+61883136278
Prof Christine Feinle-Bisset
principal investigator · Adelaide Medical School University of Adelaide Level 5 Adelaide Health and Medical Sciences Building, Cnr George St and North Tce, Adelaide, SA 5005

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion